12:00 AM
 | 
Oct 04, 2010
 |  BC Week In Review  |  Company News  |  Deals

Artes Biotechnology GmbH, Select Vaccines deal

Artes acquired Anavax virus-like particle (VLP) technology from Select Vaccines for an undisclosed upfront payment. Anavax also is eligible...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >